Table 2.
Characteristics of the patients from whom the tissue samples were obtained. All samples were at stage IV.
| Patient | Agea | Mutations at CRC-related genesb | Sex | Diagnosis | Grade | Location | Chemotherapy |
|---|---|---|---|---|---|---|---|
| CRC-PM 1c | 51 |
KRAS G12D |
Female | Mucinous Adenocarcinoma | G2 | Colon | Yes |
| CRC-PM 2 | 47 | NONE | Female | Adenocarcinoma | G2 | Sigma | Yes |
| CRC-PM 3 | 40 | NONE | Male | Adenocarcinoma | G2 | Colon | Yes |
| CRC-PM 4 | 82 | ND | Female | Mucinous Adenocarcinoma | G3 | Right colon | No |
| CRC-PM 5c | 66 |
BRAF V600E |
Female | Adenocarcinoma | G3 | Right colon | Yes |
| CRC-PM 6 | 71 |
KRAS G12S |
Female | Adenocarcinoma | G3 | Colon | No |
| CRC-PM 7 | 47 | NONE | Male | Mucinous Adenocarcinoma | G2 | Rectum | Yes |
| CRC-PM 8 | 41 |
KRAS G12S |
Male | Mucinous adenocarcinoma | G3 | Sigma | Yes |
| CRC-PM 9c | 43 |
KRAS G12S |
Female | Mucinous Adenocarcinoma | G2 | Right colon | Yes |
| CRC-PM 10c | 60 | ND | Male | Adenocarcinoma | G3 | Colon | Yes |
| CRC-PM 11c | 63 | NONE | Female | Mucinous Adenocarcinoma | G3 | Colon | Yes |
| CRC-PM 12 | 65 | NONE | Female | Adenocarcinoma | G3 | Sigma | Yes |
| CRC-PM 13 | 82 | # | Female | Colorectal neuroendocrine carcinoma | # | # | # |
| CRC-PM 14 | 61 |
BRAF V600E |
Male | Adenocarcinoma | G2 | Colon | No |
aAge at surgery.
bKRAS and BRAF genes were analysed. Protein-activating aminoacidic change is shown.
cSee Varinelli et al. 202246.